Mimo Biosciences, S.L.

Mimo Biosciences, S.L. is listed as a small business research supplier in the Scientist.com network, with 1 site in 1 country.

Email me this page as a PDF

Search companies, drugs, suppliers and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Sites 1

Countries 1

Type of company: Small business

Biomarker Discovery Identify a biomarker associated with disease progression of disease, effectiveness of therapy or diagnosis of disease or condition.
Immunophenotyping Separate cell types based on their expression of biomarkers or based on their individual and unique expression patterns.
Predictive Biomarkers Discovery Identify candidate biomarkers suggestive of a response to a treatment.

Organotypic Culture Co-culture different cells to enable in vitro growth of an in vivo tissue or organ equivalent.

Blood Models Test for therapeutic efficacy of drug candidates in blood disorder models.
Hematopoiesis Models Measure therapeutic endpoints in animal models of hematopoiesis.
Xenografts Evaluate drug candidate in tissue graft or organ transplant model.

B-Cell Lymphoma 2 (BCL-2) Assays Use biochemical, cell based or in vivo assays to measure BCL-2 protein activity.
HuGEMM - Immuno-Oncology Model Evaluate human-specific therapeutics for checkpoint inhibitors, including anti-human PD-1, anti-human PDL-1, and anti-human CTLA-4 antibodies.
Immuno-oncology Assays Use biochemical, cell based or in vivo assays to measure the activity of immuno-therapy targets.
Immuno-oncology Targets Develop drugs that take advantage of the immune system to target cancer cells.
In Vitro Disease Models Screen pre-clinical candidates without the use of live animals.
In Vitro Oncology Models Use cell-based and biochemical models of cancer.

Show all 25 services 11 more

Hematopoietic Cell Toxicity Examine cytotoxic effects of pre-clinical compounds or biologics on adult stem cells.

In Vivo Immunogenicity Study An in vivo immunogenicity study evaluates a substance's ability to trigger an immune response within a living organism.

CAR-T Efficacy In Vivo assessment of CAR-T and CAR-NK efficacy in a humanized mouse
Experimental Metastatic Models Measure therapeutic endpoints in animal models of experimental metastatic cancer.
Hematological Cancer PDX Design and validate companion diagnostics for hematological cancer that help select the most appropriate patients, identify patients at increased risk, or monitor treatment effectiveness.
Immuno-PDX Utilize the patient-derived xenograft for drug response profiling and biomarker discovery of immuno-oncology drug candidates.
Leukemia PDX Measure therapeutic endpoints in patient-derived xenografts of leukemia.
Oncology Derived PDX Patient derived xenografts derived from various oncological samples. This includes, but is not limited to, samples from Lymphoma, Melanoma, and Leukemia.

Show all 9 in Oncology Models 3 more

Oncology Models Use model organisms to test the therapeutic efficacy of cancer drug candidates.
Oncology Xenografts Xenografts derived from oncological samples.
Xenograft Models Measure therapeutic endpoints in cancer models using tumor cells transplanted from a donor of a different species.

Work with Mimo Biosciences, S.L. on Scientist.com

For prices, more details, or to contact Mimo Biosciences, S.L., visit Scientist.com.